Labcorp to spin off clinical-development business - WSJ

Laboratory of America Holdings

28/07/2022 09:09

July 28 (Reuters) - Labcorp  LH.N  plans to spin off its
unit focused on clinical drug trials, the Wall Street Journal
reported on Thursday, citing people familiar with the matter.
    The business that is being spun off reported a revenue of
roughly $3 billion in the 12 months ended in June, the report
said, a figure that is expected to grow at a high-single-digit
rate.
    Labcorp did not immediately respond to Reuters' request for
a comment.

 (Reporting by Akriti Sharma in Bengaluru; editing by
Uttaresh.V)
 ((Akriti.Sharma@thomsonreuters.com;))